Published in Medical Letter on the CDC and FDA, October 30th, 2005
In the past year, Neotropix has experienced a number of significant events including:
- Completing research and development necessary to file an investigational new drug application for Neotropix's cancer drug candidate with the FDA, setting the company on course for phase I clinical trial early in 2006.
- Securing a second tranche of funding of $3.8 million from VIMAC Milestone Medica Fund, Quaker BioVentures, The Aurora Funds, and BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania.
- Significantly increasing personnel in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.